BR112022017673A2 - Inibidor de interação de proteína com c cinase ? 1, micela, e, composição farmacêutica - Google Patents
Inibidor de interação de proteína com c cinase ? 1, micela, e, composição farmacêuticaInfo
- Publication number
- BR112022017673A2 BR112022017673A2 BR112022017673A BR112022017673A BR112022017673A2 BR 112022017673 A2 BR112022017673 A2 BR 112022017673A2 BR 112022017673 A BR112022017673 A BR 112022017673A BR 112022017673 A BR112022017673 A BR 112022017673A BR 112022017673 A2 BR112022017673 A2 BR 112022017673A2
- Authority
- BR
- Brazil
- Prior art keywords
- pick1
- kinase
- inhibitor
- protein interaction
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20161493 | 2020-03-06 | ||
| PCT/EP2021/055678 WO2021176094A1 (en) | 2020-03-06 | 2021-03-05 | Lipid conjugated peptide inhibitors of pick1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017673A2 true BR112022017673A2 (pt) | 2022-11-08 |
Family
ID=69780027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017673A BR112022017673A2 (pt) | 2020-03-06 | 2021-03-05 | Inibidor de interação de proteína com c cinase ? 1, micela, e, composição farmacêutica |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230346948A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4114524A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023506598A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220150313A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115362001A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021232645B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022017673A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3168324A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011051A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021176094A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2111413A2 (en) * | 2007-02-16 | 2009-10-28 | Genetech, Inc. | Htra1-pdz and htra3-pdz modulators |
| KR102046830B1 (ko) * | 2011-05-13 | 2019-11-20 | 코벤하븐스 유니버시테트 | 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 psd-95의 고-친화성, 이량체 저해제 |
| PL3074032T3 (pl) * | 2013-12-01 | 2019-06-28 | University Of Copenhagen | Pochodne kwasów tłuszczowych dimerycznych inhibitorów psd-95 |
| WO2020083905A1 (en) | 2018-10-22 | 2020-04-30 | University Of Copenhagen | Inhibitors of pick1 and uses thereof |
-
2021
- 2021-03-05 WO PCT/EP2021/055678 patent/WO2021176094A1/en not_active Ceased
- 2021-03-05 BR BR112022017673A patent/BR112022017673A2/pt unknown
- 2021-03-05 CA CA3168324A patent/CA3168324A1/en active Pending
- 2021-03-05 AU AU2021232645A patent/AU2021232645B2/en active Active
- 2021-03-05 US US17/905,660 patent/US20230346948A1/en active Pending
- 2021-03-05 MX MX2022011051A patent/MX2022011051A/es unknown
- 2021-03-05 KR KR1020227031597A patent/KR20220150313A/ko active Pending
- 2021-03-05 JP JP2022553063A patent/JP2023506598A/ja active Pending
- 2021-03-05 CN CN202180027127.0A patent/CN115362001A/zh active Pending
- 2021-03-05 EP EP21709689.0A patent/EP4114524A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021232645B2 (en) | 2026-07-09 |
| WO2021176094A1 (en) | 2021-09-10 |
| US20230346948A1 (en) | 2023-11-02 |
| AU2021232645A1 (en) | 2022-09-15 |
| CA3168324A1 (en) | 2021-09-10 |
| KR20220150313A (ko) | 2022-11-10 |
| CN115362001A (zh) | 2022-11-18 |
| EP4114524A1 (en) | 2023-01-11 |
| JP2023506598A (ja) | 2023-02-16 |
| MX2022011051A (es) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons | |
| Youn et al. | Suppression of MyD88-and TRIF-dependent signaling pathways of Toll-like receptor by (−)-epigallocatechin-3-gallate, a polyphenol component of green tea | |
| Wang et al. | Inhibition of activated astrocyte ameliorates lipopolysaccharide-induced depressive-like behaviors | |
| Yan et al. | The role of SIRT1 in neuroinflammation and cognitive dysfunction in aged rats after anesthesia and surgery | |
| Zhai et al. | Protective effects of paeonol on inflammatory response in IL-1β-induced human fibroblast-like synoviocytes and rheumatoid arthritis progression via modulating NF-κB pathway | |
| Hurtado et al. | Citicoline (CDP‐choline) increases S irtuin1 expression concomitant to neuroprotection in experimental stroke | |
| Yang et al. | Resveratrol inhibits BK-induced COX-2 transcription by suppressing acetylation of AP-1 and NF-κB in human rheumatoid arthritis synovial fibroblasts | |
| Yeh et al. | The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo | |
| Honda et al. | Sensitization of TRPV1 and TRPA1 via peripheral mGluR5 signaling contributes to thermal and mechanical hypersensitivity | |
| Park et al. | Rubiarbonone C inhibits platelet‐derived growth factor‐induced proliferation and migration of vascular smooth muscle cells through the focal adhesion kinase, MAPK and STAT3 Tyr705 signalling pathways | |
| BR112021015238A2 (pt) | Novos anticorpos de ligação a cd40 | |
| Li et al. | Inhibition of CHOP accentuates the apoptotic effect of α-mangostin from the mangosteen fruit (Garcinia mangostana) in 22Rv1 prostate cancer cells | |
| BR112023001143A2 (pt) | Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo | |
| Kim et al. | Indirubin-3-monoxime exhibits anti-inflammatory properties by down-regulating NF-κB and JNK signaling pathways in lipopolysaccharide-treated RAW264. 7 cells | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| Kirschneck et al. | Effects of the highly COX‐2‐selective analgesic NSAID Etoricoxib on human periodontal ligament fibroblasts during compressive orthodontic mechanical strain | |
| Wang et al. | Tectorigenin attenuates palmitate-induced endothelial insulin resistance via targeting ROS-associated inflammation and IRS-1 pathway | |
| Kotagale et al. | Agmatine ameliorates manifestation of depression-like behavior and hippocampal neuroinflammation in mouse model of Alzheimer’s disease | |
| Zhang et al. | α-Cyperone (CYP) down-regulates NF-κB and MAPKs signaling, attenuating inflammation and extracellular matrix degradation in chondrocytes, to ameliorate osteoarthritis in mice | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| Yang et al. | Methanol extract of Hopea odorata suppresses inflammatory responses via the direct inhibition of multiple kinases | |
| Hsu et al. | α-Bulnesene, a novel PAF receptor antagonist isolated from Pogostemon cablin | |
| Nachar et al. | The action of antidiabetic plants of the canadian james bay cree traditional pharmacopeia on key enzymes of hepatic glucose homeostasis | |
| Zhong et al. | Isosteviol sodium protects neural cells against hypoxia-induced apoptosis through inhibiting MAPK and NF-κB pathways | |
| Gonçalves et al. | Vatairea macrocarpa lectin (VML) induces depressive-like behavior and expression of neuroinflammatory markers in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |